子宫操纵器对子宫内膜癌手术肿瘤学结局的影响
本回顾性多中心研究纳入15个中心2661例子宫内膜癌患者,其中1756例使用子宫操纵器行子宫切除术、905例未使用;使用组复发率为11.69%,未使用组为7.4%(P<.001),使用子宫操纵器与复发风险升高相关(HR 2.31,95%CI 1.27-4.20,P=.006)。
要点
- 使用子宫操纵器组复发率11.69%,未使用组7.4%(P<.001)。
- 使用子宫操纵器与复发风险升高相关(HR 2.31,95%CI 1.27-4.20,P=.006)。
- 作者认为需前瞻性试验确认上述结果。
核心结论
- 在本研究中,子宫操纵器的使用与接受微创手术的子宫局限型子宫内膜癌(FIGO I-II期)患者较差的肿瘤学结局相关。
- 作者认为需前瞻性试验确认这些结果。
研究设计与样本
- 回顾性多中心研究,纳入15个中心的2661例拟早期子宫内膜癌患者,1756例使用子宫操纵器行子宫切除术,905例未使用。
- 评估内容包括操纵器类型、手术分期、组织学、淋巴血管间隙浸润、FIGO分期、辅助治疗、复发及复发模式;主要目标为复发率,次要目标为无复发生存、总生存及复发模式。
主要发现
- 使用子宫操纵器组复发率为11.69%,未使用组为7.4%(P<.001)。
- 使用子宫操纵器与较高的复发风险相关(HR 2.31,95%CI 1.27-4.20,P=.006)。
- 在子宫局限型子宫内膜癌(FIGO I-II期)中,使用子宫操纵器与较低的无病生存相关(HR 1.74,95%CI 0.57-0.97,P=.027),并与较高的死亡风险相关(HR 1.74,95%CI 1.07-2.83,P=.026)。
- 两组复发模式无差异(卡方统计量1.74,P=.63)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出当前证据来自样本量有限的回顾性研究。
- 原文指出需前瞻性试验确认这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data available to indicate whether oncological outcomes might be influenced by the uterine manipulator, which is used at the time of hysterectomy for minimally invasive surgery in patients with endometrial cancer. The current evidence derives from retrospective studies with limited sample sizes. Without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. OBJECTIVE: To evaluate the use of the uterine manipulator on oncological outcomes after minimally invasive surgery, for apparent early-stage endometrial cancer. STUDY DESIGN: We performed a retrospective multicentric study to assess the oncological safety of uterine manipulator use in patients with apparent early-stage endometrial cancer, treated with minimally invasive surgery. The type of manipulator, surgical staging, histology, lymphovascular space invasion, International Federation of Gynecology and Obstetrics stage, adjuvant treatment, recurrence, and pattern of recurrence were evaluated. The primary objective was to determine the relapse rate. The secondary objective was to determine recurrence-free survival, overall survival, and the pattern of recurrence. RESULTS: A total of 2661 women from 15 centers were included; 1756 patients underwent hysterectomy with a uterine manipulator and 905 without it. Both groups were balanced with respect to histology, tumor grade, myometrial invasion, International Federation of Gynecology and Obstetrics stage, and adjuvant therapy. The rate of recurrence was 11.69% in the uterine manipulator group and 7.4% in the no-manipulator group (P<.001). The use of the uterine manipulator was associated with a higher risk of recurrence (hazard ratio, 2.31; 95% confidence interval, 1.27-4.20; P=.006). The use of uterine manipulator in uterus-confined endometrial cancer (International Federation of Gynecology and Obstetrics [FIGO] I-II) was associated with lower disease-free survival (hazard ratio, 1.74; 95% confidence interval, 0.57-0.97; P=.027) and higher risk of death (hazard ratio, 1.74; 95% confidence interval, 1.07-2.83; P=.026). No differences were found regarding the pattern of recurrence between both groups (chi-square statistic, 1.74; P=.63). CONCLUSION: In this study, the use of a uterine manipulator was associated with a worse oncological outcome in patients with uterus-confined endometrial cancer (International Federation of Gynecology and Obstetrics I-II) who underwent minimally invasive surgery. Prospective trials are essential to confirm these results.
引用
- Padilla-Iserte P, Lago V, Tauste C, et al. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery. Am J Obstet Gynecol. 2020. PMID: 32693096. doi:10.1016/j.ajog.2020.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。